



Contacts: Meg McGilley
Chief Financial Officer
(858) 480-0402

Rob Whetstone
PondelWilkinson, Inc.
(310) 279-5963

Somaxon Pharmaceuticals to Present at the ThinkEquity Partners 4th Annual Growth Conference

SAN DIEGO, CA – September 7, 2006 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the ThinkEquity Partners 4th Annual Growth Conference at the Ritz-Carlton Hotel, in San Francisco, on Monday, September 11, 2006, at 3:00 p.m. Pacific Time.

A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at www.somaxon.com. The webcast will be archived and accessible for at least 14 days.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR[™] (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and has completed a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.

For more information, please visit the company's web site at www.somaxon.com.

###